WELCOME TO

OCCURX


Our primary focus is on the development of innovative therapeutic strategies for the treatment of ophthalmic disorders associated with retinal fibrosis.

OccuRx, a Melbourne-based biopharmaceutical company, was established in 2014 with venture funding from the Medical Research Commercialisation Fund, Brandon Capital Partners and Uniseed. The Company’s primary focus is on the development of innovative therapeutic strategies for the treatment of ophthalmic disorders associated with retinal fibrosis. Fibrosis and inflammation are progressive and pathological processes that are prevalent in many chronic diseases, including type -1 and type – 2 diabetes.

Diabetic retinopathy (DR) is a fibrovascular disease associated with diabetes and remains one of the leading causes of vision loss or even blindness in this group of individuals. There is a high unmet clinical need for novel and cost effective products to enhance visual acuity and prevent vision loss associated with DR, and with this focus OccuRx has patented a library of new chemical entities with potent anti-inflammatory and anti-fibrotic properties to treat DR and other fibrotic diseases of the retina.

KEEP UP TO DATE WITH OUR ADVANCES ON TWITTER.

MEET

OUR PEOPLE

Prof Darren Kelly
CEO AND MANAGING DIRECTOR

Dr Chris Nave
CHAIRPERSON AND DIRECTOR

Dr John Kurek
DIRECTOR

Darren is the Company’s CEO and Managing Director bringing over 25 years of management and research expertise in the life sciences …

Chis is a founding partner of Brandon Capital Partners and Principal Executive of the Medical Research Commercialisation Fund …

John is the Biotechnology Investment Manager of Uniseed a venture fund operating at the Universities of Melbourne, Queensland and …

Ms Ann Hamer
CHIEF OPERATING OFFICER

Dr Fay Khong
HEAD, RESEARCH & DEVELOPMENT

Mr Marc Gleeson
R&D/BUSINESS DEVELOPMENT CONSULTANT

Ann’s expertise is in organisational and operational management having spent over 12 years in various management roles within …

Fay brings to OccuRx over 7 years of medical research training and expertise in the preclinical testing of novel pharmaceutical interventions …

Marc brings to OccuRx over 23 years of experience within the Biotech and Life Sciences sector. Starting his career as a sales …